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Abstract
Esophageal carcinoma (EC) is characterized by a high rate of lymph node metastasis and its spread pattern is not
always predictable. Chemoradiotherapy has an important role in the treatment of EC in both the inoperable and the
pre-operative settings. However, regarding the target volume for radiation, different clinical practices exist. Theoretically,
in addition to the clinical target volume administered to the gross lesion, it might seem logical to deliver a certain dose
to the uninvolved regional lymph node area at risk for microscopic disease. However, in practice, it is difficult because
of the intolerance of normal tissue to radiotherapy (RT), particularly if all regions containing the cervical, mediastinal,
and upper abdominal nodes are covered. To date, the use of elective nodal irradiation (ENI) is still controversial in the
field of radiotherapy. Some investigators use involved-field radiotherapy (IFRT) in order to reduce treatment-related
toxicities. It is thought that micrometastases can be controlled, to some extent, by chemotherapy and the
abscopal effects of radiation. It is the presence of overtly involved lymph nodes rather than the micrometastatic nodes
negatively affects survival in patients with EC. In another hand, lymph nodes stationed near primary tumors also receive
considerable incidental irradiation doses that may contribute to the elimination of subclinical lesions. These
data indicate that an irradiation volume covering only the gross tumor is appropriate. When using ENI or IFRT, very few
patients experience solitary regional node failure and out-of-field lymph node failure is not common. Primary tumor
recurrence and distant metastases, rather than regional lymph node failure, affect the overall survival in patients with
EC. The available evidence indicates that the use of ENI seems to prevent or delay regional nodal relapse rather than
improve survival. In a word, these data suggest that IFRT is feasible in EC patients.
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Introduction
Esophageal carcinoma (EC) is a highly lethal disease that
has two predominant histological types: adenocarcinoma
and squamous cell carcinoma (SCC). These two predom-
inant types may be different diseases, each with a distinct
pathogenesis, epidemiology, prognosis and tumor biology,
including the pattern of lymph node metastasis [1].
Globally, SCC is the more common histology and the inci-
dence of esophageal cancer is 10 times higher in certain
geographic areas in Asia than it is in the U.S., particularly
in the “Asian esophageal cancer belt”, which extends from
northeast China to the Middle East. Indeed, SCC accounts
for 95 % of all ECs in China. Approximately 90 % of all
ECs arise in the thoracic esophagus, with the middle
thoracic esophagus being the most frequent location [2].
Chemoradiotherapy (CRT) has an important role in
the treatment of EC in both the inoperable and the pre-
operative settings. Radiotherapy (RT) alone is reserved
for palliation or for patients who cannot receive
concomitant chemotherapy. Although the International
Commission on Radiation Units and Measurements
gives suggestions for RT planning, some RT factors are
controversial, such as the radiation doses and target
volumes. For preoperative therapy, 40–45 Gy is delivered
in 1.8–2.0 Gy/day fractions in most studies. For patients
undergoing definitive CRT, 50.4 Gy is the accepted
standard dose based on randomized data from Europe
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and North America [3, 4]. Although radiation dose-
escalation has failed to improve local control or survival,
a dose of 60 Gy is more popular in Asian countries
where SCC is the predominant histological type [5, 6].
On the other hand, the target volume of external beam
radiation therapy and its coverage are controversial
among radiation oncologists. To date, no universally ac-
cepted opinion regarding the extent of the RT field has
been established, especially for the clinical target volume
(CTV). In theory, the CTV includes the gross tumor
volume (GTV) in addition to areas at risk of a micro-
scopic metastasis of the disease. For the CTV of a
primary tumor, cranial and caudal margins of 3–5 cm
and radial margins of 1–1.5 cm are generally used con-
sidering submucosal spread [4, 7, 8]. However, for the
lymph node CTV, there are various clinical practices. In
the era of two-dimensional RT, it has been standard
practice to deliver a certain dose to the uninvolved re-
gional lymph node area at risk for microscopic disease.
This is known as elective nodal irradiation (ENI). Des-
pite the high risk of nodal spread in EC, the benefit of
additional ENI is controversial, especially for overall sur-
vival (OS). With the understanding of the biologic charac-
teristics of tumors, technological and chemotherapeutic
advances have progressively changed the practice of RT,
which has been adopted for treating locally advanced
non-small cell lung cancer [9], small cell lung cancer
[10], non-Hodgkin lymphoma [11], and Hodgkin lymph-
oma [12] in the form of involved-field RT (IFRT). New
advances in CRT for EC have also come from research
into novel ways to minimize toxicity and maximize effi-
cacy. In fact, a few studies [13–17] have used IFRT in
definitive CRT or pre-operative CRT for EC patients with
either early or locally advanced staged disease. In these
studies, all the lymph nodes that were clinically involved
were included in the GTV. No prophylactic irradiation
was administered to the non-involved regional lymph
nodes. However, IFRT is controversial for the increased
risk of nodal failure in untreated nodal stations, as clinic-
ally uninvolved lymph nodes may harbor microscopic
disease.
In this review, the main arguments for omitting
ENI in EC patients are discussed, with a particular
focus on esophageal SCC. The topics covered include
the lymphatic drainage of the esophagus, lymph node
micrometastases, the effect of chemotherapy and radi-
ation on micro-metastasis, and the failure patterns
and OS after definitive CRT.
Regional lymph node involvement and the clinical target
volume
EC commonly shows lymph node metastases, particu-
larly regional lymph node involvement, which is an early
process. For example, the rate of positive loco-regional
nodes is close to 0 % for intra-epithelial tumors, 31–
56 % for T1b tumors, 58–78 % for T2, 74–81 % for T3,
and 83–100 % for T4 tumors in patients with esophageal
SCC [18, 19].
For the anatomical lymphatic drainage system of the
esophagus, the abundant lymphatic channels in the lam-
ina propria mucosae and submucosa of the esophagus
are well known from classic studies. Long longitudinal
lymphatic extension in the esophageal submucosa is very
evident, and a morphological connection between sub-
mucosal lymphatic vessels and recurrent nerve nodes
has been observed [20, 21]. The lymphatic routes to the
peri-esophageal lymph nodes usually originate from the
intermuscular area of the muscularis propria, and lymph-
atic communication between the submucosa and inter-
muscular area is rarely apparent histologically [21, 22].
These morphologies suggest an explanation for the ana-
tomically distant lymph node metastasis known as ‘skip
metastasis’ observed in EC. Therefore, in patients with tu-
mors confined to the submucosal layer, even with tumors
located in the lower esophagus, lymphatic metastasis
frequently occurs in the supraclavicular area. The “distant”
lymph node involvement from superficial carcinoma is
thus not necessarily a sign of advanced disease. In the 7th
edition of the TNM staging system, regional lymph nodes
were redefined as any paraesophageal lymph node, includ-
ing the cervical and celiac nodes. For the radiation target
volume, theoretically, it might be logical to include not
only the mediastinal lymph nodes, but also the cervical
and upper abdominal nodes. However, the large radiation
volume may increase acute toxicity and late adverse events
that involve the heart, lungs, and hematologic system [23].
In the Radiation Therapy Oncology Group trial 85-01, the
acute toxicity was substantial: 64 % of patients treated
with CRT experienced severe or life-threatening side
effects, and only 23 % of patients enrolled were over
70 years of age [24].
To minimize toxicity, tighter fields with less elective
CTV coverage (that is, ENI) were used in the later stud-
ies, in which the lymph nodes at risk were included in
the CTV, depending on the location of the primary
tumor. However, there are no universal recommenda-
tions for the lymph node CTV for EC. The American
National Comprehensive Cancer Network recommends
ENI, as follows: for the supraclavicular area, consider
treatment of higher echelon cervical nodes, especially if
the nodal stage is N1 or greater for cervical lesions; for
the proximal third of the esophagus, treat the para-
esophageal lymph nodes and supraclavicular areas; for
middle lesions, treat the para-esophageal lymph nodes;
and for the distal and the gastro-esophageal junction, treat
the lesser curvature, celiac axis, and para-esophageal
lymph nodes. However, in a recent meta-analysis, Ding
et al. [25] surveyed 18,415 patients in 45 observational
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studies to determine which node level should be included
in the target volume for patients undergoing definitive
CRT. Their data came from patients undergoing surgical
treatment with two-field or three-field dissection. The
lymph node metastasis rates of thoracic EC in the cervical,
upper-mediastinal, mid-mediastinal, lower mediastinal,
and abdominal levels were 30.7, 42.0, 12.9, 2.6, and 9 %
for upper thoracic EC; 16.8, 21.1, 28.1, 7.8, and 21.4 % for
middle thoracic EC; and 11.0, 10.5, 19.6, 23.0, and 39.9 %
for lower thoracic EC, respectively. These results suggest
that multiple region involvement and skip node metastasis
were frequently observed in EC patients. In theory, a large
T-shaped field would be necessary for thoracic EC, which
would include bilateral supraclavicular areas, the whole
mediastinum, and the left gastric lymph nodes. On the
other hand, in addition to the location and depth of tumor
invasion, the length of the tumor and histological differen-
tiation were also associated with lymph node metastasis in
esophageal SCC [26, 27].
In summary, EC is characterized by a high rate of
nodal involvement, and its spread pattern is not always
predictable. Although it is thought that there is one pre-
dominant area of drainage depending on the location of
the primary tumor, it is difficult to accurately define the
CTV of RT in a specific patient. It is also difficult to en-
compass all possible longitudinal local extensions and
lymphatic and nodal drainage routes owing to the treat-
ment intolerance of normal tissue.
Lymph node metastasis and micrometastases
The correct staging of patients with esophageal SCC
provides accurate information on the extent of the dis-
ease and guides the treatment plan. If IFRT is used, the
detection of the involved lymph nodes is important for
curative intent. It was reported that, for the detection of
regional lymph node metastases, endoscopic ultrasound
(EUS) is the most sensitive method, whereas computed
tomography (CT) and fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) have higher specificity. The
random effects pooled sensitivities of EUS, CT, and FDG-
PET for regional lymph node metastases were 0.80 (95 %
confidence interval 0.75–0.84), 0.50 (0.41–0.60), and 0.57
(0.43–0.70), respectively, and the specificities were 0.70
(0.65–0.75), 0.83 (0.77–0.89), and 0.85 (0.76–0.95), re-
spectively [28]. In clinical practice, PET-CT is popular for
the diagnosis and evaluation of EC. However, there are
conflicting results in the imaging literature regarding the
accuracy of PET for staging the regional lymph nodes.
The major problem is the obscuration of the adjacent
lymph nodes by uptake in the primary tumor, leading to
low sensitivity. However, PET is useful in detecting
regional nodal disease that is not immediately near the
primary esophageal tumor. In one study, the sensitivity,
specificity, and accuracy of PET-CT were 94, 92, and
92 %, respectively, in a nodal group-by-group basis [29].
Each imaging modality has its advantages and disadvan-
tages; therefore, CT, EUS, and PET should be considered
complementary diagnostic methods.
Even so, undetected occult disease recurrence and micro-
metastases to regional lymph nodes may exist owing to the
intrinsic limitation of the accuracy of using all these diag-
nostic methods. Such micrometastases might be present in
a certain number of patients at the time of presentation
[30]. In patients with EC, a few studies showed that lymph
node micrometastases are associated with a significant
negative impact on survival [30–32]. However, some stud-
ies have reported that micrometastases might increase the
risk of lymph node recurrence, but it does not influence
the survival of patients with pN0 esophageal SCC [33, 34].
Although the data of lymphatic mapping of EC indi-
cate that the site of micrometastases is totally unpredict-
able, it is thought that extensive lymphadenectomy
could eliminate the micrometastases to regional lymph
nodes. There is evidence from a recent meta-analysis
suggesting that a better OS can be achieved with three-
field lymphadenectomy vs. two-field lymphadenectomy
[35]. This may suggest the benefits of ENI. There are no
randomized trials investigating the effect of three-field
lymphadenectomy in local tumor control and disease-
free survival. Nonetheless, some recent reports have sug-
gested that more extensive lymph node clearance during
surgery for EC may not improve survival [36, 37]. A few
studies have reported that, only a subset of patients will
most likely really benefit from extensive lymphadenec-
tomy, which could well be related to the number of
lymph nodes involved. Nishimaki et al. [38] reported
that no patients with five involved lymph nodes survived
for more than 5 years following three-field lymphade-
nectomy. Rizk et al. also found that patients with more
than four involved lymph nodes have survival rates
similar to those of patients with M1 disease undergoing
surgery [39]. Natsugoe et al. [40] reported that the
number of pre-surgical lymph node metastases is re-
lated to prognosis in patients with EC, in which the
5-year survival rates of patients with 0, 1–3, 4–7, and
≥8 lymph node metastases determined by US and
EUS were 53.3, 33.8 17.0, and 0 %, respectively. These
results suggest that the presence of multiple lymph
node involvement indicates systemic disease, and that
survival remains unchanged despite the extensive re-
moval of lymph nodes. The number of lymph nodes
involved is likely more important for survival than
the regional field of involvement. Although it has
been confirmed that ENI is effective for preventing
regional nodal failure [41, 42], for local advanced EC,
the micrometastases at distant sites would nullify the
benefits of clearance of locoregional disease. There is
no doubt that efforts should be made to optimize
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treatment schedules in order to eliminate distant
micrometastases.
These data indicated that the presence of overtly in-
volved lymph nodes rather than the micrometastatic
nodes negatively affects survival in patients with EC.
The use of intensive radiation and chemotherapy or im-
mune therapy to increase the complete response rate
and reduce distant metastases may be essential to im-
prove survival in EC patients.
Chemoradiotherapy and the incidence of regional nodal
failure
Chemotherapy or CRT is able to significantly reduce
nodal micrometastases, regardless of whether SCC or
adenocarcinoma histology is present [43, 44]. If tu-
mors show a major histomorphologic response follow-
ing neoadjuvant chemoradiation, the presence of
nodal micrometastases is significantly reduced com-
pared to those with a minor response [43]. Tsuchiya
et al. [45] reported that preoperative chemotherapy
reduced the number of metastatic lymph nodes, and
the metastasis rate in the resected lymph nodes was
significantly higher in patients who underwent surgery
alone than in those who received preoperative chemo-
therapy. Furthermore, the mean number of metastatic
lymph nodes was significantly lower in the chemotherapy
responders than in non-responders. In responders, tumors
exhibited such a high degree of CRT sensitivity that not
only the primary tumor, but also distant micrometastases,
were eliminated by the neoadjuvant therapy. It is possible
that, in the patients with a partial response (PR) and with
variable tumor sensitivity, the persistence of distant micro-
metastases caused distant tumor recurrence. In an aggres-
sive cancer, any remaining distant micro-metastasis after
neoadjuvant therapy ensured that patients with a PR expe-
rienced recurrence outside of the treated field with the
same virulence as those non-responding patients not
affected by neoadjuvant therapy.
In contrast, the clinical relevance of micrometastases
may depend on the balance between tumor aggressive-
ness, the host immune status, and the response to treat-
ment. Theoretically, a host’s immune system may be
able to remove a single tumor cell and diminish residual
cells with metastatic potential. Mounting evidence indi-
cates that RT also recruits biological effectors outside
the treatment field and has systemic effects [46, 47].
When tumor cells die due to RT, they also emit a spe-
cific combination of signals that elicits tumor-specific
cytotoxic T lymphocyte responses. The immune effec-
tors that are generated in this setting can act systemic-
ally, hence eradicating distant, non-irradiated lesions
(long-range, out-of-field or abscopal effects). In im-
munocompetent hosts, the efficacy of RT appears to rely
for the most part on abscopal effects. If the tumor is
sensitive to radiation, to some extent, IFRT could also
significantly reduce nodal and distant micrometastases.
Thirdly, incidental irradiation may play a role in the
control of micrometastases in thoracic lymph nodes. Al-
though the use of intensity-modulated RT and IFRT can
reduce the incidental irradiation of the regional nodal
area, irradiation around the primary lesions may have
still been effective in eradicating subclinical lymph node
metastasis. For the primary tumor, radiation fields
extended 3–5 cm beyond the proximal and distal extent
of the lesion, and the lateral borders extended 1–2 cm
beyond the apparent mass in most studies. As such, the
periesophageal lymph nodes should be included in the
radiation field. Ji et al. [48] showed that that the incidental
irradiation dose to high-risk nodal regions is considerable
for T1-3N0M0 esophageal SCC using three-dimensional
CRT. Based on a meta-analysis by Ding et al. [25], lymph
node metastasis most frequently occurred in paratracheal,
paraesophageal, perigastric, and subcarinal stations. In
clinical practice, however, most patients presented with
long lesions and/or positive lymph node metastasis, in
which more high-risk regions would receive considerable
doses if metastatic nodes were included in the GTV.
Therefore, IFRT may still deliver a considerable incidental
dose to high-risk elective regions, which will have a signifi-
cant impact on the control of micrometastases.
In conclusion, it is thought that, to some extent,
micrometastases can be controlled by chemotherapy and
the abscopal effects of radiation in responders. For non-
responders, the persistent gross disease and the distant
micrometastases cause the immediate recurrence, which
may mask regional nodal failures. On the other hand,
lymph node stations near primary tumors also receive
considerable incidental irradiation doses that may con-
tribute to the elimination of subclinical lesions. These
data indicate that an irradiation volume covering only
the gross tumor is appropriate.
Patterns of failure
The response rate decreases with the progression of dis-
ease. Many trials have reported a good response rate from
concurrent CRT in esophageal SCC [3, 4, 16, 49–56].
Based on these data, the response rate by stage was more
than 90 % for T1, 60–90 % for T2–3, and 57–88 % for T4.
The complete response (CR) rate by stage was 89.7–97 %
for T1, 50–60 % for T2–3, and 17–39 % for T4, respect-
ively. The response status is well correlated with the
failure patterns. Rohatgi et al. demonstrated that the pro-
portion of residual carcinoma after preoperative CRT is
significantly correlated with the patterns of locoregional
and distant failure [57]. Similar results were also found in
patients receiving definitive CRT for EC [58]. The time to
locoregional recurrence was significantly longer for pa-
tients who achieved a pathologic complete response
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compared with non-responders. The rate of distant metas-
tases was significantly lower in responders compared to
non-responders.
For T1 stage disease, most patients achieved a CR after
definitive (C)RT. Nonetheless, half of the failures oc-
curred in the local primary tumor, and the secondary
failure pattern was the distant lymph nodes or organs
[14, 16, 49]. The incidence of regional lymph node
failure is low (1–6 %), with or without ENI. Ishikawa
et al. assessed the patterns of failure after IFRT in 68
patients with stage I EC. In their study, out of 50 pa-
tients with submucosal cancer (T1b), only 1 patient
(2 %) developed regional lymph node failure outside the
radiation field [59]. Okawa et al. conducted a multi-
institutional study of 105 patients with superficial EC
treated with ENI. Lymph node failure outside the radi-
ation field occurred in 6 patients (6 %), whereas lymph
node failure inside the ENI area occurred in only 1 pa-
tient (1 %) [60]. Kawaguchi [16] also observed regional
lymph node failure alone in 4 % (3/68) of patients with
clinical stage I thoracic esophageal SCC after IFRT. In
contrast, for early stage esophageal SCC, a second pri-
mary cancer was often observed. In the JCOG9708
study, a second primary cancer was observed in 18 of 72
patients [49]. Yamamoto et al. also found that most local
recurrences in the CRT group were intramucosal meta-
chronous carcinomas for the stage I population, and
they were cured after salvage treatment with no effect
on OS [61]. As such, the incidence of regional lymph
node failure is low, which suggests that conservative
IFRT should be feasible for T1 stage EC.
In locally advanced patients with SCC histology, CRT
generally results in CR rates of ∼ 20–50 %. Unfortu-
nately, a considerable proportion of EC patients were re-
sistant to CRT, and as many as 11–26 % of those
patients did not exhibit any morphological response,
which results in persistent disease or immediate local
failure. Welsh et al. reported the results of failure patterns
in patients with EC treated with definitive CRT using ENI
[62]. At a median follow-up time of 52.6 months, 50 %
had experienced local failure, 48 % had distant failure, and
31 % had no evidence of failure. Of all local failures, 90 %
were within the GTV, 23 % were within the CTV, and
12 % were within in the planning target volume. However,
the histological type was adenocarcinoma (76 %) rather
than SCC (24 %) in that study. In a report by Versteijne
et al. [63], in which half (52 %) of the patients had SCC,
the conformal CTV consisted of the GTV plus at least the
periesophageal lymph node area extended in the cranio-
caudal direction by a 3.5-cm margin. With a mean follow-
up time of 22.8 months, 41 % of patients had evidence of
a locoregional recurrence. The median time to locoregio-
nal recurrence was 9.6 months. Among the patients with
a locoregional recurrence, most showed failure at the site
of the GTV (86 %). A failure at the site of the primary
tumor alone occurred in 57 %, in lymph nodes alone (in-
and outfield) in 14 %, and at both sites in 29 %. Of the
total group of 184 patients, 76 patients (41 %) experienced
distant metastases, of which 37 (20 %) occurred in com-
bination with a locoregional recurrence. In this study with
reduced ENI, the out-field locoregional recurrences oc-
curred in 17 of 184 patients (9.2 %). In 8 of these patients
(4.3 %), it was a solitary locoregional recurrence without
an infield recurrence, which is comparable with the results
observed with ENI. In another IFRT study based on FDG-
PET staging for inoperable esophageal SCC with lymph
node metastases, Yamashita et al. [17] found only 2 of 63
patients with failure in lymph node regions not included
in the target volume.
For patients received preoperative IFRT, Oppedijk et al.
reported a 1 % (2/213) failure rate for isolated out field
locoregional recurrence in the CROSS trials. Though
locoregional recurrence occurred in 6 % outside the radi-
ation target volume, most of them (11/13) combined with
distant failure in this trial [64]. Even for cases with a CR
after CRT, the primary lesion and the distant organ rather
than the regional lymph node were the prominent sites of
recurrence. In a study by Di Fiore et al. [65], the target
volume of RT was the macroscopic tumor and enlarged
lymph nodes. For the 86 clinical CR patients, 34 (39.5 %)
experienced a local disease recurrence, 37 patients (43 %)
experienced metastatic disease, and 19 of them experi-
enced both of these. Using ENI combined with chemo-
therapy, Yamashita et al. [41] found that, after achieving a
CR, 40 patients experienced failures (local failure in 20
and distant failure in 20), and no patient experienced
elective nodal failure without having any other site of re-
currence. Onozawa et al. [42] reported failure patterns
using ENI for the 20 patients with recurrence after a CR;
the first sites of failure were local (10 patients), distant (9
patients), and elective nodal failure (1 patient). Of note,
the vast majority (80 %) of the patients with in-field lymph
node pathology had a synchronous failure at the primary
tumor site. It may be hypothesized that part of this lymph
node metastasis was secondary to failure at the site of
their primary tumor.
In conclusion, for early and advanced EC, with either
ENI or IFRT, the majority of the failures occurred in the
GTV (especially in the primary tumor) and at distant
sites after CRT, even for cases with a CR. The lymph
node failure in or out of field was not common, and only
few patients experienced solitary regional node failure.
Overall survival
According to trials of local or advanced EC treated with
CRT using ENI, 1-year OS rate was 41–88 %, 2-year OS
was 28–63 %, 3-year OS was 19–48 %, and 5-year OS
was up to 26 %; the median survival time was 9.0–33
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months, depending on the disease stage [3–5, 50–53]. In
an IFRT study using FDG-PET, Yamashita et al. [17]
showed that the 3-year progression-free survival (PFS)
and OS rates were 47.7 and 51.1 %, respectively, with a
median PFS and OS of 34.6 and 38.4 months, respect-
ively. In another IFRT study, Zhao et al. [13] found that
the median survival and PFS were 30 months and
17 months, respectively, with 1-, 3-, and 5-year OS and
PFS rates of 77, 56, 41, and 77, 55, 36 %, respectively.
For patients aged 75 years and older, Uno et al. [66]
demonstrated that they could also benefit from IFRT
combined chemotherapy, and a CR was obtained in 6 of
22 patients (27.3 %), with a median survival time of
9 months and a 1-year OS rate of 39 %. These data were
comparable with those of the ENI studies. Ma et al. [67]
directly compared ENI with IFRT in patients with
cervical and upper-thoracic EC and found a median sur-
vival time of 33.7 months for the IFRT group versus
32.7 months for the ENI group in a prospectively ran-
domized trial. However, no significant difference was
found in the 3-year OS and local-regional control rates
between the IFRT and ENI groups (32.0 and 80.1 % vs.
41.3 and 85.7 %, respectively). In a JASTRO study [68],
they found that there was no difference between the sur-
vival rates of patients who had received RT to the primary
lesion alone and those of patients who had received RT to
the primary lesion and regional lymph nodes in either
patients with mucosal or submucosal cancer.
Regarding the impact of regional lymph node failure
on OS, there have been few studies comparing IFRT and
ENI. Liu et al. [69] retrospectively evaluated the value of
ENI for cervical and upper thoracic EC, and they found
that out-of-field regional cervical node metastasis oc-
curred in 8 % of patients in the IFRT group. However, it
occurred in 10 % of patients in the ENI group. ENI for
cervical and upper thoracic esophageal SCC patients did
not lead to longer OS or better long-term control of cer-
vical lymph nodes. Although ENI might delay cervical
node progression in the elective field, it does not de-
crease the incidence of these failures. Hsu et al. [70]
retrospectively analyzed the of outcome differences in
preoperative concurrent CRT with or without ENI for
esophageal SCC. They found that more patients in the
non-ENI group had M1a (cervical or abdominal regions)
failure than in the ENI group, with 3-year rates of 11
and 3 %, respectively (p = 0.05). However, the M1a fail-
ure was not associated with poor outcomes in patients
undergoing preoperative CRT for esophageal SCC.
Matched cases analysis did not show a statistical differ-
ence in the outcomes between the groups. Zhang et al.
[14] observed the contribution of different failure pat-
terns to survival. In their study, the median OS time for
patients with in-field failure was 14.2 months vs.
17.4 months (p = 0.010) for those with non in-field
failure. Patients without distant failure achieved a bet-
ter OS than those with distant failure (16.2 m vs.
13.2 m. p < 0.001). However, no significant difference was
found in the median OS time for patients with or without
an out-of-field regional lymph node failure pattern.
While OS should remain a primary endpoint, treatment-
related toxicity should also be considered. ENI studies
reported that 25–60 % and 23–29 % of patients experienced
grade 3 or greater acute and late toxicities, respect-
ively [3, 4, 24, 71]. In Kaneko’s study [50], which used
extended field of irradiation and concurrent chemo-
therapy for patients with malignant strictures of esopha-
geal carcinoma. Grade 3 and above leukocytopenia,
anemia, thrombocytopenia, and esophagitis occurred in
30, 33, 14, and 25 % of patients, respectively. Zhao
et al.[13] reported rates of grade 3 acute and late toxicities
of 9 and 6 % after IFRT, respectively, and no patients had
acute or late grade 4 or 5 toxicities. The patient compli-
ance and tolerance is well when IFRT was used in the trial
FFCD 9901 [72]. In group CRT, 91.8 % patients received a
total radiation dose, with 92.9 % patients completing the
first cycle of chemotherapy and 85.7 % completing the
second cycle. During the first and second cycles of chemo-
therapy, 14.3 and 13.3 % patients experienced grade 3 or 4
toxicities, respectively. There were no treatment-related
deaths before surgery. Ma et al. [67] also showed that
there were significant less severe in the IFRT group
than ENI groups regarding hematologic toxicity, infec-
tion and vomiting. Thus, IFRT may reduce incidences
of treatment toxicities and enable more patients to
tolerate chemoradiotherapy.
These studies indicate that primary tumor recurrence
and distant metastasis, rather than regional lymph nodal
failure, affect the OS in patients with local advanced EC.
No significant difference was found in the OS of patients
treated with ENI or IFRT and IFRT may reduce inci-
dences of treatment toxicities, which suggests that IFRT
is the rational choice.
Conclusion
In conclusion, the GTV was the most common site of
initial failure after CRT in EC patients, and advanced-
stage patients experienced high rates of systemic failure.
It remains unclear how much of the potential improved
OS with the addition of ENI is caused from the im-
proved regional tumor control. It is reasonable that only
patients with a histologically proven CR in terms of
GTV can acquire PFS benefits from eliminating the re-
gional nodal micrometastases. However, the responders
also have fewer incidences of any patterns of failure
compared to non-responders. Consequently, the role of
ENI in the prevention of regional failure was also chal-
lenged in patients with good responses. In addition, for
non-responders or non-complete responders, if the
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primary lesions could not be well controlled, ENI seems
unnecessary. Although ENI should be able to decrease
the regional nodal failure, non-responders have shorter
survival, and many of the patients died before their re-
gional nodal failure became clinically apparent or threat-
ened their life.
In a word, these data suggested that IFRT is feasible in
EC patients. The use of intensive radiation and chemo-
therapy to increase the complete response rate and re-
duce distant metastases may be essential to improve
survival. Future research also should improve our ability
to increase the diagnostic accuracy of metastatic lymph
nodes, predict the risk of lymph node involvement, and
identify responders prior to treatment. Validation of this
opinion by future prospective and randomized studies is,
however, required.
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